CSS LLC’s Vertex Pharmaceuticals VRTX Stock Holding History

CSS LLC’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$268K	Buy	+600	New	+$280K	0.01%	688
2025 Q3	–	Sell	-1,000	Closed	-$445K	–	1215
2025 Q2	$445K	Buy	+1,000	New	+$461K	0.02%	593
2024 Q1	–	Sell	-18,000	Closed	-$7.32M	–	964
2023 Q4	$7.32M	Hold	18,000	–	–	0.42%	44
2023 Q3	$6.26M	Hold	18,000	–	–	0.41%	50
2023 Q2	$6.33M	Hold	18,000	–	–	0.39%	50
2023 Q1	$5.67M	Buy	18,000 +15,500	+620%	+$4.65M	0.37%	62
2022 Q4	$722K	Buy	+2,500	New	+$762K	0.04%	320
2021 Q4	–	Sell	-51,100	Closed	-$9.27M	–	1328
2021 Q3	$9.27M	Buy	51,100 +3,300	+7%	+$644K	0.39%	51
2021 Q2	$9.64M	Buy	+47,800	New	+$10M	0.4%	52

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

CSS LLC's VRTX Position: Q1 2025 in Review

CSS LLC sold out of Vertex Pharmaceuticals (VRTX) in Q1 2025, closing a stake of 550 shares — an estimated $221K sold.

CSS LLC first reported a position in VRTX in Q1 2020 and held it in 16 quarters. The position peaked at $8.9M in Q3 2021. 1,613 funds tracked by Wall St. Rank hold VRTX as of Q1 2025.

CSS LLC reported no remaining Vertex Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
CSS LLC sold 550 Vertex Pharmaceuticals shares in Q1 2025, an estimated $221K.
CSS LLC first reported a position in Vertex Pharmaceuticals in Q1 2020 and held it in 16 quarters.
CSS LLC's Vertex Pharmaceuticals position peaked at $8.9M in Q3 2021.
1,613 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2025.

Based on CSS LLC's 13F filing for Q1 2025, filed 15 May 2025.